Novo Nordisk A/S (NVO) receives a strong valuation ranking of 67 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. NVO has a better value than 67% of stocks based on these valuation analytics. Investors primarily focused on buy-and-hold strategies will find the valuation ranking relevant to their goals when making investment decisions.
NVO has a 12 month forward PE to Growth (PEG) ratio of 1.66. Markets are overvaluing NVO in relation to its projected growth as its PEG ratio is currently above the fair market value of 1. 3.68's PEG comes from its forward price to earnings ratio being divided by its growth rate. PEG ratios are one of the most used valuation metrics due to its incorporation of more company fundamentals metrics and a focus on the firm's future rather than its past.
Is Novo Nordisk A/S (NVO) Stock Over or Undervalued?
Mentioned in this article
NVO gets a 67 Valuation Rank today. Find out what this means to you and get the rest of the rankings on NVO!